1. Meeting Report: N-Nitrosamine Impurity Control Strategies in the Pharmaceutical and Biotechnology Industries.
- Author
-
Roberts SW, Lennard A, Mohan G, Bernstein J, Cauchon NS, Cole S, Curristin N, Huynh-Ba K, Kolz CN, Murti C, and Tang K
- Subjects
- Congresses as Topic, Nitrosamines analysis, Nitrosamines toxicity, Pharmaceutical Preparations analysis, Societies, Pharmaceutical, United States, United States Food and Drug Administration standards, Drug Contamination prevention & control, Nitrosamines standards, Pharmaceutical Preparations standards, Quality Control
- Abstract
The American Association of Pharmaceutical Scientists (AAPS) Chemistry, Manufacturing, and Control (CMC) Community hosted a virtual panel discussion on December 9, 2020, to provide a forum to discuss N-nitrosamine control strategies in the pharmaceutical and biotechnology industries. The panel included staff from the US Food and Drug Administration (FDA) and industry subject matter experts. Meeting topics included acceptable intake levels for nitrosamine impurities, definitions of "acceptable level of risk," water as a contributor in nitrosamine risk assessments, nitrosamine impurity control strategies based upon fate/purge data, early vs. late development assessment expectations, application to oncology programs developed under ICH S9, and Drug Master File (DMF) regulatory expectations. During the meeting, divergence in global health authority expectations was additionally discussed. One of the most important outputs from this AAPS panel discussion was the criticality of continued dialog between industry and health authorities to help understand actual versus perceived risks and provide pragmatic, scientifically justified solutions to ensure patients are provided with an uninterrupted supply of safe medicines based on globally harmonized requirements., (© 2021. American Association of Pharmaceutical Scientists.)
- Published
- 2021
- Full Text
- View/download PDF